Nomogram developed to estimate early breast cancer survival

Share this article:
Nomogram Developed to Estimate Early Breast Cancer Survival
Nomogram Developed to Estimate Early Breast Cancer Survival

(HealthDay News) -- A nomogram has been developed to predict five- and 10-year mastectomy-free survival (MFS) in older women with early breast cancer and estimate the predicted benefit of radiation therapy (RT) following conservative surgery (CS), according to research published online June 25 in the Journal of Clinical Oncology.

In an effort to develop a nomogram to predict five- and 10-year MFS rates with and without RT, Jeffrey M. Albert, M.D., of the University of Texas MD Anderson Cancer Center in Houston, and colleagues utilized population-based data from 16,092 women aged 66 to 79 years who participated in the Surveillance, Epidemiology and End Results Program.

The researchers found that overall five- and 10-year MFS rates were 98.1 and 95.4 percent, respectively, after a median follow-up period of 7.2 years. Significant predictors of time to mastectomy included age, race, tumor size, estrogen receptor status, receipt of radiotherapy, and nodal status. The nomogram developed was able to accurately predict MFS.

"In summary, we used population-based data to develop a nomogram to estimate five- and 10-year MFS among older women with early breast cancer treated with CS," the authors write. "This clinically useful tool uses readily available clinicopathologic factors to estimate the probability of MFS and can further aid individualized clinical decision making by estimating the potential benefit from RT for this large and growing patient population."

One study author disclosed a financial tie to Varian Medical Systems, which contributed funding to the study.

Abstract
Full Text (subscription or payment may be required)
Editorial

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Challenges exist in treating HPV oropharyngeal cancer patients

Challenges exist in treating HPV oropharyngeal cancer patients

Mixed views have been expressed in relation to explaining the causal role of HPV in oropharyngeal cancer.

Views on Affordable Care Act split by political affiliation

Views on Affordable Care Act split by political ...

Health care is third most important issue to Americans in fall elections, according to polls

Poor staging linked to mortality in bladder cancer

Poor staging linked to mortality in bladder cancer

In cases of bladder cancer, omission of muscle in specimen or its mention in pathology report is linked to increased mortality.